Exor to more than double its direct bioMérieux stake without taking control

The Agnelli family’s holding company will trade part of its interest in private Institut Mérieux for listed shares in the French diagnostics group. The family behind bioMérieux will retain a voting majority through the Institut.

Sources

Sources & evidence

What “Source checked” means

Exor will more than double its direct stake in French diagnostics maker bioMérieux to 8.53% from 3.87% by giving up part of its holding in the company that controls it. The deal shifts more of Exor’s investment into listed shares but leaves Institut Mérieux in control of the diagnostics group.

What Exor is exchanging

Exor, the Agnelli family’s holding company, will receive bioMérieux shares that Institut Mérieux already owns.

In return, it will surrender some of its shares in the privately held Institut, which is reducing its share capital.

The announcement describes an exchange of existing stakes rather than a financing for bioMérieux. It discloses neither a cash price nor a valuation for the exchange, so the larger direct stake should not be read as a new investment of that size in the operating business.

The Institut is where the relationship began. In July 2022, Exor said it had closed an agreement for a 10% holding there, representing an €833 million commitment. It took a direct position in bioMérieux in 2025.

If the deal closes, Exor will retain 5.02% of Institut Mérieux’s capital and 2.58% of its votes.

That leaves Exor with exposure to bioMérieux through two routes: shares in the listed company itself and a smaller holding in its controlling shareholder.

More shares do not translate into the same share of votes

Exor’s 8.53% of bioMérieux’s share capital would carry 5.35% of its voting rights after closing. The capital figure measures its share of the company’s equity. The voting figure is the one to watch when it comes to shareholder decisions.

Institut Mérieux would retain 55.24% of the capital and 68.67% of the voting rights.

The proposed transfer therefore leaves the Institut with a clear majority by either measure. Exor and the Mérieux family said they do not intend to act in concert regarding bioMérieux.

The clearest potential governance change is a board seat. The bioMérieux board is expected to propose Benoît Ribadeau-Dumas as Exor’s representative at the next annual general meeting. He already sits on the Institut board and is a nonvoting observer at bioMérieux.

A proposed appointment is not the same as an approved seat.

Why the private stake already mattered

Even before the exchange, Exor’s private holding gave it substantial exposure to the diagnostics company. Its first-half report put bioMérieux at 69% of Institut Mérieux’s portfolio. Exor valued its interest in the Institut at €680 million at the end of June, down from €956 million at year-end, citing share-price weakness at bioMérieux and Transgene partly offset by Moderna’s gains.

The 69% figure is a portfolio weighting, not an ownership percentage. It shows why the diagnostics maker already mattered to Exor’s private investment, but it does not measure how much bioMérieux equity Exor owned indirectly or provide a valuation for Thursday’s exchange.

bioMérieux’s latest business review reported third-quarter sales of €1.042 billion, up 8.1% at constant exchange rates and consolidation scope, or 9.9% as reported. Nine-month sales reached €3.006 billion, up 2.7% on that comparable basis and 0.5% as reported.

In that longer period, BIOFIRE non-respiratory panel sales rose 12%, while respiratory panels fell 14%.

Those figures put the faster third quarter in perspective: the company reported growth across several lines, but weaker respiratory testing was still a drag across the first nine months. bioMérieux confirmed its full-year guidance on Nov. 3. The stake announcement did not update it.

What to watch after the announcement

The companies expect the exchange to close in December, after the creditor objection period and subject to formal approval from Institut Mérieux shareholders. The stakes and votes announced Thursday are what the companies expect after closing, not a register of ownership today.

After closing, the next governance milestone is whether bioMérieux shareholders approve the proposed Exor representative. For investors tracking Exor’s portfolio, its next financial disclosure will give a clearer view of how it values the new mix of direct shares and the remaining private holding.

Sources & evidence

Source checked4 sources · 20 figures

Figure receipts

Every figure in this article, with the source it came from.

  • €1.042 billion bioMérieux quarterly sales, rounded from disclosed €1,041.7m

    EUR · EUR, reported · As of Q3 2026

  • 8.1% bioMérieux quarterly sales growth at constant exchange rates and consolidation scope

    % year over year, like for like · As of Q3 2026

  • 9.9% bioMérieux quarterly sales growth as reported

    % year over year, reported · As of Q3 2026

  • €3.006 billion bioMérieux nine-month sales, rounded from disclosed €3,006.3m

    EUR · EUR, reported · As of Nine months to Sept. 30, 2026

  • 2.7% bioMérieux nine-month sales growth at constant exchange rates and consolidation scope

    % year over year, like for like · As of Nine months to Sept. 30, 2026

  • 0.5% bioMérieux nine-month sales growth as reported

    % year over year, reported · As of Nine months to Sept. 30, 2026

  • +12% BIOFIRE non-respiratory panel sales growth

    % year over year, like for like · As of Nine months to Sept. 30, 2026

  • −14% BIOFIRE respiratory panel sales decline

    % year over year, like for like · As of Nine months to Sept. 30, 2026

  • 10% Exor stake in Institut Mérieux under the original agreement

    % of share capital · As of July 2022 agreement

  • €833 million Exor’s total agreed investment in Institut Mérieux in 2022

    EUR · EUR, commitment · As of July 2022 agreement

  • 3.87% Exor direct stake in bioMérieux before the exchange

    % of share capital · As of Nov. 19, 2026, announcement

  • 8.53% Exor direct stake in bioMérieux if the exchange closes

    % of share capital · As of Post-close, expected

  • 5.35% Exor voting rights in bioMérieux if the exchange closes

    % of voting rights · As of Post-close, expected

  • 55.24% Institut Mérieux stake in bioMérieux if the exchange closes

    % of share capital · As of Post-close, expected

  • 68.67% Institut Mérieux voting rights in bioMérieux if the exchange closes

    % of voting rights · As of Post-close, expected

  • 5.02% Exor’s residual interest in Institut Mérieux after the exchange

    % of share capital · As of Post-close, expected

  • 2.58% Exor’s residual voting rights in Institut Mérieux after the exchange

    % of voting rights · As of Post-close, expected

  • 69% bioMérieux weighting in the Institut Mérieux portfolio, per Exor

    % of portfolio · As of First-half 2026 report

  • €680 million Exor’s fair value for its Institut Mérieux holding

    EUR · EUR, fair value · As of June 30, 2026

  • €956 million Exor’s prior fair value for its Institut Mérieux holding

    EUR · EUR, fair value · As of Dec. 31, 2025

Based on the Nov. 19 deal announcement. Expected post-close ownership is not current ownership; financial context comes from the dated disclosures.

TickerGrove house illustration for banking coverage: a bank facade with columns and an arched door

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories